Immune Design Corp. (IMDZ) financial statements (2022 and earlier)

Company profile

Business Address 1616 EASTLAKE AVENUE E.
SEATTLE, WA 98102
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments95,887141,107107,255112,92175,354
Cash and cash equivalents77,94172,45445,214112,92175,354
Short-term investments17,94668,65362,041  
Restricted cash and investments 6,000   
Receivables7053,7813,6739721,970
Inventory, net of allowances, customer advances and progress billings926846071325
Inventory926846071325
Prepaid expense1,7551,5712,5461,654633
Other current assets1,786    
Total current assets:100,225153,143114,081115,56077,982
Noncurrent Assets
Property, plant and equipment535491414585401
Deposits noncurrent assets200200   
Total noncurrent assets:735691414585401
TOTAL ASSETS:100,960153,834114,495116,14578,383
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities8,8458,5209,4947,06013,283
Accounts payable1,4782,3344,5593,0746,903
Accrued liabilities7,3676,1864,9353,9865,001
Employee-related liabilities    1,379
Estimated litigation liability 6,0007,250  
Deferred revenue and credits 2,51951567
Other undisclosed current liabilities    (1,903)
Total current liabilities:8,84514,52019,2637,11111,947
Noncurrent Liabilities
Liabilities, other than long-term debt110102564190
Deferred revenue and credits   90
Other liabilities1101025641 
Total noncurrent liabilities:110102564190
Total liabilities:8,95514,62219,3197,15212,037
Stockholders' equity
Stockholders' equity attributable to parent, including:92,005139,21295,176108,99366,346
Additional paid in capital382,474374,970278,913239,181157,092
Accumulated other comprehensive loss(2)(49)(24)  
Accumulated deficit(290,515)(235,757)(183,738)(130,208)(90,763)
Other undisclosed stockholders' equity attributable to parent4848252017
Total stockholders' equity:92,005139,21295,176108,99366,346
TOTAL LIABILITIES AND EQUITY:100,960153,834114,495116,14578,383

Income statement (P&L) ($ in thousands)

12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Revenues2,1967,19513,2609,5106,433
Revenue, net7,19513,2609,5106,433
Cost of revenue
(Cost of Goods and Services Sold)
(1,435)(84)(481)(774)(638)
Gross profit:7617,11112,7798,7365,795
Operating expenses(59,246)(60,007)(67,474)(48,995)(36,311)
Other undisclosed operating income1,43584481774638
Operating loss:(57,050)(52,812)(54,214)(39,485)(29,878)
Nonoperating income
(Other Nonoperating income)
2,292950684404
Net loss:(54,758)(51,862)(53,530)(39,445)(29,874)
Other undisclosed net loss attributable to parent    (4,277)
Net loss available to common stockholders, diluted:(54,758)(51,862)(53,530)(39,445)(34,151)

Comprehensive Income ($ in thousands)

12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss:(54,758)(51,862)(53,530)(39,445)(29,874)
Comprehensive loss:(54,758)(51,862)(53,530)(39,445)(29,874)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent47(25)(24)  
Comprehensive loss, net of tax, attributable to parent:(54,711)(51,887)(53,554)(39,445)(29,874)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: